Key result
Advanced multimodality imaging, combined with biomarkers, provides essential tools for the early detection, risk stratification, and monitoring of cancer therapy-related cardiotoxicity.
Why the study?
Anticancer treatments are associated with cardiovascular disorders, making prompt detection and treatment pivotal to enable healthy survivorship and reduce cardiovascular morbidity.
Answers are grounded in this paper and cite their sources.
This review highlights the critical role of multimodality imaging and biomarkers in the early detection, monitoring, and prognostication of cancer therapy-related cardiotoxicity.
Modern cancer therapies have significantly improved survival leading to a growing population of cancer survivors. Similarly, both conventional and newer treatments are associated with a spectrum of cardiovascular disorders with potential long-term sequelae. Prompt detection and treatment of these complications is, therefore, pivotal to enable healthy survivorship and reduce cardiovascular morbidity. Advanced multimodality imaging is a valuable tool for stratifying patient risk, identifying cardiovascular toxicity during and after therapy, and predicting recovery. This review summarizes the potential cardiotoxic complications of anticancer therapies and the multimodality approaches available in each case with special focus on newer techniques and the added value of biomarkers ultimately leading to earlier diagnosis and better prognostication.
No takes yet. Share an insight, caveat, or question.
Artico et al. (2022) conducted a review in Cancer therapeutics related cardiac dysfunction (CTRCD). Multimodality imaging (Echocardiography, CMR, Cardiac CT, Nuclear) was evaluated. Advanced multimodality imaging, combined with biomarkers, provides essential tools for the early detection, risk stratification, and monitoring of cancer therapy-related cardiotoxicity.
Synapse has enriched 10 related papers. Consider them for comparative context: